In drug development, preclinical tests are carried out to investigate the behavior of novel agents in cell culture or animal models.
Detailed description
The aim of preclinical tests is to identify substances showing a therapeutic effect. Cell cultures and animal models are used to investigate whether these substances are toxic, damage the genetic material or induce malformations. This phase lasts ten years on average. Only few of the substances examined are suitable for further testing in humans and the subsequent clinical phase.
Antimicrobial resistance (AMR) is one of the most urgent challenges facing global health and development. Described as a “creeping pandemic” by the G7 forum of leading economic nations, AMR occurs
HYpharm's innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against the bacterial pathogenStaphylococcus aureus including multi-resistant
A team led by Prof Achim Hoerauf in the German Center for Infection Research (DZIF) is further developing the antibiotic corallopyronin A as a treatment for the neglected tropical diseases river
More than one billion people worldwide are at risk of illness, disfigurement, disability, and even death from neglected tropical diseases (NTDs). Especially in the poorest regions of the world where
Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures
Antibiotic resistance is increasing at an alarming rate worldwide. New treatment options are urgently needed. Due to their specificity for certain bacteria, phages represent a conceivable alternative or supplement to antibiotics. The specificity of phages, but also the fact that they have no toxic ...
Please use this image only in connection with this news.
Vaccines against the SARS-CoV-2 virus have been made possible by an unprecedented worldwide collaboration. But medications against Covid-19 have as yet seen only partial success. A Munich research
Please use this picture only in connection with the press release.
The clinical review of the MVA-SARS-2-S vector vaccine against COVID-19 will continue with a new version. The DZIF (German Center for Infection Research) scientists temporarily suspended the study
Please use this picture only in connection with the press release.
The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, today approved the clinical trial of the MVA-SARS-2-S vaccine against COVID-19. The vector vaccine was developed by
Since 2014, DZIF scientists are developing a promising antibiotic for tuberculosis, which has also proven to be effective effective against multidrug-resistant pathogens in preclinical tests. The new
The Tropical Institute at the Hospital of the Ludwig-Maximilians-University (LMU) Munich is currently conducting a clinical study led by Professor Michael Hoelscher. Since mid-November, the first
